
REFERENCES

American Diabetes Association: Clinical Practice Recommendations 2003. *Diabetes Care* 26 (Supplement 1), 2003

Refer also to specific guidelines pages for additional citations.

Screening and Diagnosis

American Diabetes Association (Position Statement). Screening for type 2 diabetes. *Diabetes Care* 26 (Supplement 1): S21-S24, 2003.

American Diabetes Association (Committee Report). Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 26 (Supplement 1): S5-S20, 2003.

National Institutes of Health, National Heart, Lung and Blood Institute. *Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults*, 1998.

Glycemic Control

American Diabetes Association (Position statement). Implications of the United Kingdom Prospective Diabetes Study. *Diabetes Care* 26 (Supplement 1): S28-S32, 2003.

American Diabetes Association (Position statement). Standards of medical care for patients with diabetes mellitus. *Diabetes Care* 26 (Supplement 1): S33-S50, 2003.

Colwell, J.A. DCCT findings: Applicability and implications for NIDDM. *Diabetes Reviews* 2(3): 277-291, 1994.

Colwell, J.A. The feasibility of intensive insulin management of non-insulin-dependent diabetes mellitus: Implications of the Veterans Affairs cooperative study on glycemic control and complications in NIDDM. *Ann Intern Med* 124(1 pt 2): 131-135, 1996.

Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. *Diabetes* 44: 968-983, 1995.

Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 329: 977-986, 1993.

Nathan, D.M. Initial management of glycemia in type 2 diabetes mellitus. *N Engl J Med* 347: 1342-1349, 2002.

Ohkubo, Y., et al. Intensive insulin therapy prevents the progression of diabetes microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. *Diabetes Research and Clinical Practice* 28: 103-117, 1995.

Nutrition

American Diabetes Association (Position Statement). Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications, *Diabetes Care* 26 (Supplement 1): S51-S61, 2003.

American Dietetic Association. *Diabetes Medical Nutrition Therapy*. Chicago: American Dietetic Association, 1997.

American Dietetic Association. *Nutrition Practice Guidelines for Type I and Type II Diabetes*. Chicago: American Dietetic Association, 1996.

Johnson, E.Q. and Valera, S. Medical nutrition therapy in non-insulin-dependent diabetes mellitus improves clinical outcome. *JADA* 95(6): 700-701, 1995.

Exercise

American Diabetes Association (Position Statement). Diabetes mellitus and exercise. *Diabetes Care* 26 (Supplement 1): S49-S53, 2003.

American Diabetes Association. *The Health Professional's Guide to Diabetes and Exercise*. Alexandria, VA: American Diabetes Association, Inc., 1995.

Barnard, R.J., Jung, T., and Inkeles, S.B. Diet and exercise in the treatment of NIDDM: The need for early emphasis. *Diabetes Care* 17(12): 1469-1472, 1994.

Medications

American Diabetes Association (Position Statement). Insulin administration. *Diabetes Care* 26 (Supplement 1): S121-S124, 2003.

American Diabetes Association (Position Statement). Management of dyslipidemia in adults with diabetes. *Diabetes Care* 26 (Supplement 1): S83-S86, 2003.

Bayer Corporation. Prescribing information for acarbose (Precose). March 2003.

Bell, D. Beta blockers in the diabetic patient. *Practical Diabetology* 20-23, March 2003.

Bristol-Myers Squibb Co. Prescribing information for metformin (Glucophage). July 2002.

Bristol-Myers Squibb Co. Prescribing information for glyburide and metformin (Glucovance). October 2002.

Bristol-Myers Squibb Co. Prescribing information for glipizide and metformin (Metaglip). October 2002.

Cheatham, W. Repaglinide: A new oral blood glucose-lowering agent. *Clinical Diabetes* 16(2): 70-72, 1998.

Coniff, R.F., Krol, A.: Acarbose: A review of US clinical experience. *Clin Ther* 19: 16-26, 1997.

Coniff, R.F., Shapiro, J.A., Seaton, T.B., Bray, G.A. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in noninsulin-dependent diabetes mellitus. *Am J Med* 98: 443-451, 1995.

Eli Lilly and Company. Prescribing information for insulin lispro protamine/insulin lispro mix (Humalog 75/25). May 2002.

GlaxoSmithKline. Prescribing information for rosiglitazone (Avandia). March 2003.

(continued on reverse)

- GlaxoSmithKline. Prescribing information for rosiglitazone and metformin (Avandamet). October 2002.
- Novartis Pharmaceuticals Corporation. Prescribing information for nateglinide (Starlix). December 2000.
- Novo Nordisk Pharmaceuticals, Inc. Prescribing information for repaglinide (Prandin). October 2003.
- Novo Nordisk Pharmaceuticals, Inc. Prescribing information for insulin aspart protamine/insulin aspart mix (NovoLog 70/30). May 2002.
- Pharmacia & Upjohn Co. Prescribing information for miglitol (Glyset). September 2002.
- Takeda Pharmaceuticals America, Inc. Prescribing information for pioglitazone (Actos). July 2002.
- United Kingdom Prospective Diabetes Study Group. UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. *Diabetes Care* 21: 87-92, 1998.

Diabetes Self-Management Training

- American Association of Diabetes Educators. *A Core Curriculum for Diabetes Education, Fourth Edition*. Chicago, IL: American Association of Diabetes Educators, 2001.
- American Diabetes Association. *Diabetes Education Goals*. Alexandria, VA: American Diabetes Association, Inc., 1995.
- American Diabetes Association: *Medical Management of Type 1 Diabetes, 3rd Edition*. Alexandria, Virginia: American Diabetes Association, Inc., 1998.
- American Diabetes Association. *Medical Management of Type 2 Diabetes, 4th Edition*. Alexandria, Virginia: American Diabetes Association, Inc., 1998.
- American Diabetes Association (Position Statement). Standards of medical care for patients with diabetes mellitus. *Diabetes Care* 26 (Supplement 1): S33-S50, 2003.
- Danese, M.D., Powe, N.R., Sawin, C.T., and Ladenson, P.W. Screening for mild thyroid failure at the periodic health exam. A decision and cost-effectiveness analysis. *JAMA* 276: 285-292, 1996.
- Einhorn, D., and Gold, E.M. Type II diabetes: New tools, new strategies. *Family Practice Recertification* 19: 83-107, 1997.
- Norris, S. Self-management education in type 2 diabetes: What works? *Practical Diabetology* 7-13, March, 2003.

Complications

Cardiovascular Disease

- American Diabetes Association (Position Statement). Management of dyslipidemia in adults with diabetes. *Diabetes Care* 26 (Supplement 1): S33-S50, 2003.
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Adult Treatment Panel (ATP III)/*JAMA* 285: 2486-2497, 2001.
- Fatourech, V., et al. A practical guideline for management of hypertension in patients with diabetes. *Mayo Clin Proc* 71: 53-58, 1996.
- Frishman, W. et al. Drug treatment of orthostatic hypotension and vasovagal response. *Heart Disease* 5(1): 49-64, 2003.
- Gæde et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med* 348(5): 383-393, 2003.
- Grundy, S.M., et al. When to start cholesterol-lowering therapy in patients with coronary heart disease. *Circulation* 95: 1683-1685, 1997.
- The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. *NEJM* 336(3): 153-162, 1997.
- Savage, P. Cardiovascular complications of diabetes mellitus: What we know and what we need to know about their prevention. *Ann Intern Med* 124(1 pt 2): 123-126, 1996.
- Singer, D., et al. Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham heart study. *Diabetes* 41: 202-208, 1992.

Foot Problems

- American Diabetes Association (Position Statement). Preventive foot care in people with diabetes. *Diabetes Care* 24 (Supplement 1): S78-S79, 2003.
- Levin, M. E. Preventing amputation in the patient with diabetes. *Diabetes Care* 18(10): 1383-1394, 1995.
- National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. *Feet Can Last A Lifetime: A Health Care Provider's Guide to Preventing Diabetes Foot Problems*, 1998.
- Reiber, G.E., Boyko, E.J., and Smith, D. Lower extremity foot ulcers and amputations in diabetes. In *Diabetes in America, 2nd Edition*. NIH Publication No. 95-1468. Pp. 409-428, 1995.

(continued on next page)

Hypertension

ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The anti-hypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *JAMA* 288(23): 2981-2997, 2002.

Appel, L. The verdict from ALLHAT – thiazide diuretics are the preferred initial therapy for hypertension. *JAMA* 288 (23): 3039-3042, 2002.

Cushman, W.C., et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *The Journal of Clinical Hypertension* IV (IV) 1-12, 2002.

UKDPS 38, United Kingdom Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. *BMJ* 317, pp 703-713, 1998.

Nephropathy

Ahmad, J., Siddiqui, M., and Ahmad, H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. *Diabetes Care* 20(10): 1576-1581, 1997.

American Diabetes Association (Consensus Statement). Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. *Diabetes Care* 17(11): 1357-1361, 1994.

American Diabetes Association (Position Statement). Diabetic nephropathy. *Diabetes Care* 26 (Supplement 1): S94-S98, 2003.

Bennett, P., et al. Screening and management of microalbuminuria in patients with diabetes mellitus: Recommendations to the scientific advisory board of the National Kidney Foundation from an ad hoc committee of the council on diabetes mellitus of the National Kidney Foundation. *American Journal of Kidney Diseases* 25(1): 107-112, 1995.

Brenner, B.M., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 345: 861-869, 2001.

Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med* 342: 145-153, 2000.

Lewis E.J., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 345: 851-860, 2001.

Periodontal Disease

U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Dental Research. *Diabetes and Periodontal Disease: A Guide for Patients*, 1997.

U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Dental Research. *Diabetes: Dental Tips*, 1998.

Pregnancy

Elixhauser, A., et al. Cost-benefit analysis of preconception care for women with established diabetes mellitus. *Diabetes Care* 16: 1146-1157, 1993.

Retinopathy

American Diabetes Association (Position Statement). Diabetic retinopathy. *Diabetes Care* 26 (Supplement 1): S99-S102, 2003.

Other

American Diabetes Association, Massachusetts affiliate. Fact Sheet on the Massachusetts Diabetes Cost Reduction Act. 2000.

American Diabetes Association (Position Statement). Immunization and the Prevention of Influenza and Pneumococcal Disease in People With Diabetes, *Diabetes Care* 26 (Supplement 1): S126-S128, 2003.